BioSig Technologies Inc., a Westport-headquartered medical technology company developing a proprietary biomedical signal processing platform to upgrade electrocardiogram and intracardiac signals, has hired Sasha Gentling as director of business development and investments.
Prior to joining the company, Gentling was investment officer at Mayo Clinic, where she managed the organization”™s investment portfolio. Prior to that role, he managed investor communications and marketing activities at the Stamford-headquartered Discerene Group. Gentling will be based in the company”™s new office in Rochester, Minnesota.
“We were impressed by Sasha”™s investment experience and her achievements in both profit and non-profit organizations,” said Kenneth L. Londoner, chairman and CEO of BioSig Technologies. Gentling is BioSig Technologies”™ second investment-focused executive to be hired within the past month, following the recruitment of Andrew Gornell Ballou as vice president of investor relations. Ballou was formerly managing director and head of institutional equity sales at Janney Montgomery Scott LLC in Philadelphia.
